Bristol-Myers Squibb Company and Pfizer have announced that they will present 14 abstracts (oral and poster presentations) at the ESC Congress 2014, organised by the European Society of Cardiology, to be held 30 August to 4 September in Barcelona, Spain. The new clinical trial data and GHEOR analyses assessing cost effectiveness and real-world use reinforcing the alliance’s commitment to the ongoing analysis of Eliquis in both the NVAF and VTE patient populations.
The complete list of Bristol-Myers Squibb/Pfizer alliance presentations is included below. Abstracts can be accessed on the ESC Congress 2014 website.
Title |
Presenting Author/Type |
Date/Time (CEST) |
Location/Session |
ARISTOTLE Biomarker Analyses |
|||
Galectin-3 is associated with worse clinical outcome in patients with atrial fibrillation: A substudy from the ARISTOTLE trial
Session: Posters Sessions |
Asberg, S/ Poster |
31 Aug 14:00 – 18:00 |
Poster area – Central Village |
A new biomarker based risk score for predicting major bleeding in atrial fibrillation – the ABC (age, biomarkers, current disease) risk score
Session: Prediction and Prevention of Atrial fibrillation (AF) |
Hijazi, Z/ Moderated Poster |
31 Aug 15:38 – 15:47 |
Moderated poster corner- Central Village |
The efficacy of apixaban compared to warfarin in patients with atrial fibrillation with high coagulation activity despite anticoagulant treatment
Session: Atrial Fibrillation: How to improve prognosis? |
Christersson, C/ Abstract Session |
2 Sep 08:45 – 09:00 |
Tbilisi – Village 7 |
Interleukin-6 and C-reactive protein and risk for cardiovascular events and death in anticoagulated patients with atrial fibrillation
Session: Posters Sessions |
Aulin, J/ Poster |
2 Sep 14:00 – 18:00 |
Poster area – Central Village |
AMPLIFY and AMPLIFY-EXT |
|||
Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial
Session: Posters Sessions |
Agnelli, G/ Poster |
2 Sep 08:30 – 12:30 |
Poster area – Central Village |
Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial
Session: Refining antithrombotic therapy in coronary artery disease |
Cohen, A/ Moderated Poster |
31 Aug 10:00 – 10:08 |
Moderated poster corner – Central Village |
Predictors of hospitalization during extended treatment of venous thromboembolism in the AMPLIFY-EXT trial
Session: Acute Pulmonary Embolism |
Cohen, A/ Oral |
30 Aug 11:18 – 11:36 |
Cairo Village |
Indirect Treatment Comparisons and Economic Value Analyses |
|||
Efficacy and safety of apixaban versus edoxaban for stroke prevention in NVAF patients: an indirect treatment analysis
Session: Novel Oral Anticoagulants: Trials, Costs and Real Life Use |
Lip GYH/ Oral |
2 Sep 11:00 – 11:15 |
Vilinius Village |
Potential impact of apixaban on formulary budget and clinical outcomes in non-valvular atrial fibrillation patients
Session: Novel Oral Anticoagulants: Trials, Costs and Real Life Use |
Kachroo, S/ Oral |
2 Sep 11:30 – 11:45 |
Vilinius Village |
Cost-effectiveness of apixaban compared to edoxaban for stroke prevention in non-valvular atrial fibrillation
Session: Posters Sessions |
Lip GYH/ Poster |
2 Sep 14:00 – 18:00 |
Central Village |
Comparison of apixaban, dabigatran and rivaroxaban in the acute treatment and prevention of venous thromboembolism: systematic review and network meta-analysis
Session: Venous Thromboembolism: What’s New |
Cohen, A/ Oral |
2 Sep 17:15 – 17:30 |
Tbilisi Village |
Cost-effectiveness of apixaban compared to other anticoagulants for the acute (6-month) treatment of venous thromboembolism
Session: Venous Thromboembolism: What’s New |
Lanitis, T/ Oral |
2 Sep 16:45 – 17:00 |
Tbilisi Village |
Real World Data Analyses |
|||
Real world discontinuation among early users of apixaban, dabigatran, rivaroxaban or warfarin among atrial fibrillation patients newly initiated on anticoagulation therapy: tell of first 200 days
Session: Novel Oral Anticoagulants: Trials, Costs and Real Life Use |
Phatak, H/ Oral |
2 Sep 12:15 – 12:30 |
Vilinius Village |
Warfarin discontinuation in patients with unprovoked venous thromboembolism: a large U.S. insurance database analysis
Session: Posters Sessions |
Liu JXC/ Poster |
2 Sep 8:30 to 12:00 |
Central Village |